Evidence map›Paper›PMID 37747243›Full record

ArticleMicrobiology spectrum2023

Risk factors for microbiological persistence after 6 months of treatment for

Xuejiao Luo, Xubin Zheng, Yong Fang, Fangyou Yu, Haiyan Cui, Qin Sun, Wei Sha

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Extrapulmonary Comparisons BetweenInfection and drug resistance · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xuejiao Luo *Department of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University , Shanghai, China.ORCID 0009-0007-7103-272X
Xubin Zheng *Department of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University , Shanghai, China.ORCID 0009-0001-4999-9834
Yong FangDepartment of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University , Shanghai, China.
Fangyou YuDepartment of Clinical Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University , Shanghai, China.
Haiyan CuiDepartment of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University , Shanghai, China.
Qin SunDepartment of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University , Shanghai, China.ORCID 0000-0003-3445-920X
Wei ShaDepartment of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University , Shanghai, China.ORCID 0000-0002-2099-8205
Tongji University · CN

Funding

Clinical Research Plan of SHDC SHDC2020CR6024MOST | National Natural Science Foundation of China (NSFC) 82204107Shanghai Clinical Research Center for Infectious Disease (tuberculosis) 19MC1910800Shanghai Key Clinical Specialty Construction Project (tuberculosis) shslezdzk03001Shanghai Science and Technology Commission Project 20Y11901500
6 · The paper itself

Abstract

importanceNontuberculous mycobacteria pulmonary disease (NTM-PD) has been recognized as an important public health issue because of its increasing incidence globally, low cure rate, and high recurrence rate. NTM-PD has innate resistance to many first-line anti-tuberculous drugs, which limits the treatment options.

Indexed as

antimycobacterial treatmentclinical characteristicsculture conversionminimum inhibitory concentrationMycobacterium intracellularenontuberculous mycobacteria

Identifiers

PMID37747243
PMCPMC10581050
OpenAlexW4387002325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.